Bispecific Antibodies Market Research Report Information By Indication (Autoimmune Diseases and Oncology), By End User (Hospitals, Specialty Clinics, and Homecare), By Route of Administration (Oral and Injectables) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3.Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2.Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL BISPECIFIC ANTIBODIES MARKET, BY INDICATION

6.1. Overview

6.2. Autoimmune Diseases

6.3. Oncology

7. GLOBAL BISPECIFIC ANTIBODIES MARKET, BY END USER

7.1. Overview

7.2. Hospitals

7.3. Specialty Clinics

7.4. Homecare

8. GLOBAL BISPECIFIC ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION

8.1. Overview

8.2. Oral

8.3. Injectables

9. GLOBAL BISPECIFIC ANTIBODIES MARKET, BY REGION

9.1. Overview

9.1. North America

9.1.1. US

9.1.2. Canada

9.2. Europe

9.2.1. Germany

9.2.2. France

9.2.3. UK

9.2.4. Italy

9.2.5. Spain

9.2.6. Rest of Europe

9.3. Asia-Pacific

9.3.1. China

9.3.2. India

9.3.3. Japan

9.3.4. South Korea

9.3.5. Australia

9.3.6. Rest of Asia-Pacific

9.4. Rest of the World

9.4.1. Middle East

9.4.2. Africa

9.4.3. Latin America

10. COMPETITIVE LANDSCAPE

10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategy in the Global Bispecific Antibodies Market,

10.5. Competitive Benchmarking

10.6. Leading Players in Terms of Number of Developments in the Global Bispecific Antibodies Market,

10.7. Key Developments and Growth Strategies

10.7.1. New Product Launch/Service Deployment

10.7.2. Merger & Acquisitions

10.7.3. Joint Ventures

10.8. Major Players Financial Matrix

10.8.1. Sales & Operating Income, 2023

10.8.2. Major Players R&D Expenditure. 2023

11. COMPANY PROFILES

11.1. Sonafi S.A.

11.1.1. Company Overview

11.1.2. Financial Overview

11.1.3. Products Offered

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. AbbVie Inc.

11.2.1. Company Overview

11.2.2. Financial Overview

11.2.3. Products Offered

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. PFIZER INC.

11.3.1. Company Overview

11.3.2. Financial Overview

11.3.3. Products Offered

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. Johnson & Johnson

11.4.1. Company Overview

11.4.2. Financial Overview

11.4.3. Products Offered

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. Portola Pharmaceuticals

11.5.1. Company Overview

11.5.2. Financial Overview

11.5.3. Products Offered

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. BRISTOL-MYERS SQUIBB

11.6.1. Company Overview

11.6.2. Financial Overview

11.6.3. Products Offered

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Ganymed Pharmaceuticals

11.7.1. Company Overview

11.7.2. Financial Overview

11.7.3. Products Offered

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. OncoMed Pharmaceuticals

11.8.1. Company Overview

11.8.2. Financial Overview

11.8.3. Products Offered

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. Merck Amgen

11.9.1. Company Overview

11.9.2. Financial Overview

11.9.3. Products Offered

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Bayer AG

11.10.1. Company Overview

11.10.2. Financial Overview

11.10.3. Products Offered

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

11.11. Daiichi Sankyo Company Limited

11.11.1. Company Overview

11.11.2. Financial Overview

11.11.3. Products Offered

11.11.4. Key Developments

11.11.5. SWOT Analysis

11.11.6. Key Strategies

12. APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL BISPECIFIC ANTIBODIES MARKET, SYNOPSIS, 2019-2032

TABLE 2 GLOBAL BISPECIFIC ANTIBODIES MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)

TABLE 3 GLOBAL BISPECIFIC ANTIBODIES MARKET, BY INDICATION, 2019-2032 (USD BILLION)

TABLE 4 GLOBAL BISPECIFIC ANTIBODIES MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 5 GLOBAL BISPECIFIC ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 6 NORTH AMERICA: BISPECIFIC ANTIBODIES MARKET, BY INDICATION, 2019-2032 (USD BILLION)

TABLE 7 NORTH AMERICA: BISPECIFIC ANTIBODIES MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 8 NORTH AMERICA: BISPECIFIC ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 9 US: BISPECIFIC ANTIBODIES MARKET, BY INDICATION, 2019-2032 (USD BILLION)

TABLE 10 US: BISPECIFIC ANTIBODIES MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 11 US: BISPECIFIC ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 12 CANADA: BISPECIFIC ANTIBODIES MARKET, BY INDICATION, 2019-2032 (USD BILLION)

TABLE 13 CANADA: BISPECIFIC ANTIBODIES MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 14 CANADA: BISPECIFIC ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 1 EUROPE: BISPECIFIC ANTIBODIES MARKET, BY INDICATION, 2019-2032 (USD BILLION)

TABLE 2 EUROPE: BISPECIFIC ANTIBODIES MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 3 EUROPE: BISPECIFIC ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 4 GERMANY: BISPECIFIC ANTIBODIES MARKET, BY INDICATION, 2019-2032 (USD BILLION)

TABLE 5 GERMANY: BISPECIFIC ANTIBODIES MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 6 GERMANY: BISPECIFIC ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 7 FRANCE: BISPECIFIC ANTIBODIES MARKET, BY INDICATION, 2019-2032 (USD BILLION)

TABLE 8 FRANCE: BISPECIFIC ANTIBODIES MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 9 FRANCE: BISPECIFIC ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 10 ITALY: BISPECIFIC ANTIBODIES MARKET, BY INDICATION, 2019-2032 (USD BILLION)

TABLE 11 ITALY: BISPECIFIC ANTIBODIES MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 12 ITALY: BISPECIFIC ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 13 SPAIN: BISPECIFIC ANTIBODIES MARKET, BY INDICATION, 2019-2032 (USD BILLION)

TABLE 14 SPAIN: BISPECIFIC ANTIBODIES MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 15 SPAIN: BISPECIFIC ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 16 UK: BISPECIFIC ANTIBODIES MARKET, BY INDICATION, 2019-2032 (USD BILLION)

TABLE 17 UK: BISPECIFIC ANTIBODIES MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 18 UK: BISPECIFIC ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 19 REST OF EUROPE: BISPECIFIC ANTIBODIES MARKET, BY INDICATION, 2019-2032 (USD BILLION)

TABLE 20 REST OF EUROPE: BISPECIFIC ANTIBODIES MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 21 REST OF EUROPE: BISPECIFIC ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 22 ASIA-PACIFIC: BISPECIFIC ANTIBODIES MARKET, BY INDICATION, 2019-2032 (USD BILLION)

TABLE 23 ASIA-PACIFIC: BISPECIFIC ANTIBODIES MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 24 ASIA-PACIFIC: BISPECIFIC ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 25 JAPAN: BISPECIFIC ANTIBODIES MARKET, BY INDICATION, 2019-2032 (USD BILLION)

TABLE 26 JAPAN: BISPECIFIC ANTIBODIES MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 27 JAPAN: BISPECIFIC ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 28 CHINA: BISPECIFIC ANTIBODIES MARKET, BY INDICATION, 2019-2032 (USD BILLION)

TABLE 29 CHINA: BISPECIFIC ANTIBODIES MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 30 CHINA: BISPECIFIC ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 31 INDIA: BISPECIFIC ANTIBODIES MARKET, BY INDICATION, 2019-2032 (USD BILLION)

TABLE 32 INDIA: BISPECIFIC ANTIBODIES MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 33 INDIA: BISPECIFIC ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 34 AUSTRALIA: BISPECIFIC ANTIBODIES MARKET, BY INDICATION, 2019-2032 (USD BILLION)

TABLE 35 AUSTRALIA: BISPECIFIC ANTIBODIES MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 36 AUSTRALIA: BISPECIFIC ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 37 SOUTH KOREA: BISPECIFIC ANTIBODIES MARKET, BY INDICATION, 2019-2032 (USD BILLION)

TABLE 38 SOUTH KOREA: BISPECIFIC ANTIBODIES MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 39 SOUTH KOREA: BISPECIFIC ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 40 REST OF ASIA-PACIFIC: BISPECIFIC ANTIBODIES MARKET, BY INDICATION, 2019-2032 (USD BILLION)

TABLE 41 REST OF ASIA-PACIFIC: BISPECIFIC ANTIBODIES MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 42 REST OF ASIA-PACIFIC: BISPECIFIC ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 43 REST OF THE WORLD: BISPECIFIC ANTIBODIES MARKET, BY INDICATION, 2019-2032 (USD BILLION)

TABLE 44 REST OF THE WORLD: BISPECIFIC ANTIBODIES MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 45 REST OF THE WORLD: BISPECIFIC ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 46 MIDDLE EAST: BISPECIFIC ANTIBODIES MARKET, BY INDICATION, 2019-2032 (USD BILLION)

TABLE 47 MIDDLE EAST: BISPECIFIC ANTIBODIES MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 48 MIDDLE EAST: BISPECIFIC ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 49 AFRICA: BISPECIFIC ANTIBODIES MARKET, BY INDICATION, 2019-2032 (USD BILLION)

TABLE 50 AFRICA: BISPECIFIC ANTIBODIES MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 51 AFRICA: BISPECIFIC ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 52 LATIN AMERICA: BISPECIFIC ANTIBODIES MARKET, BY INDICATION, 2019-2032 (USD BILLION)

TABLE 53 LATIN AMERICA: BISPECIFIC ANTIBODIES MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 54 LATIN AMERICA: BISPECIFIC ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL BISPECIFIC ANTIBODIES MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL BISPECIFIC ANTIBODIES MARKET

FIGURE 4 GLOBAL BISPECIFIC ANTIBODIES MARKET, SHARE (%), BY INDICATION, 2023

FIGURE 5 GLOBAL BISPECIFIC ANTIBODIES MARKET, SHARE (%), BY END USER, 2023

FIGURE 6 GLOBAL BISPECIFIC ANTIBODIES MARKET, SHARE (%), BY ROUTE OF ADMINISTRATION, 2023

FIGURE 7 GLOBAL BISPECIFIC ANTIBODIES MARKET, SHARE (%), BY ROUTE OF ADMINISTRATION, 2023

FIGURE 8 GLOBAL BISPECIFIC ANTIBODIES MARKET, SHARE (%), BY REGION, 2023

FIGURE 9 NORTH AMERICA: BISPECIFIC ANTIBODIES MARKET, SHARE (%), BY REGION, 2023

FIGURE 10 EUROPE: BISPECIFIC ANTIBODIES MARKET, SHARE (%), BY REGION, 2023

FIGURE 11 ASIA-PACIFIC: BISPECIFIC ANTIBODIES MARKET, SHARE (%), BY REGION, 2023

FIGURE 12 REST OF THE WORLD: BISPECIFIC ANTIBODIES MARKET, SHARE (%), BY REGION, 2023

FIGURE 13 GLOBAL BISPECIFIC ANTIBODIES MARKET: COMPANY SHARE ANALYSIS, 2023 (%)

FIGURE 14 SONAFI S.A.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 15 SONAFI S.A.: SWOT ANALYSIS

FIGURE 16 ABBVIE INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 17 ABBVIE INC.: SWOT ANALYSIS

FIGURE 18 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 19 PFIZER INC.: SWOT ANALYSIS

FIGURE 20 JOHNSON & JOHNSON: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 21 JOHNSON & JOHNSON: SWOT ANALYSIS

FIGURE 22 PORTOLA PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 23 PORTOLA PHARMACEUTICALS: SWOT ANALYSIS

FIGURE 24 BRISTOL-MYERS SQUIBB: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 BRISTOL-MYERS SQUIBB: SWOT ANALYSIS

FIGURE 26 GANYMED PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 GANYMED PHARMACEUTICALS: SWOT ANALYSIS

FIGURE 28 ONCOMED PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 ONCOMED PHARMACEUTICALS: SWOT ANALYSIS

FIGURE 30 MERCK AMGEN: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 MERCK AMGEN: SWOT ANALYSIS

FIGURE 32 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 33 BAYER AG: SWOT ANALYSIS

FIGURE 34 DAIICHI SANKYO COMPANY LIMITED: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 35 DAIICHI SANKYO COMPANY LIMITED: SWOT ANALYSIS